The FreeStyle Libre portfolio clinical evidence

Using CGM to gain glucose insights can lead to meaningful changes in diabetes outcomes.

doctor patient talking freestyle libre
doctor patient talking freestyle libre
doctor patient talking freestyle libre

Strong evidence for the use of the FreeStyle Libre portfolio*†1-14

The FreeStyle Libre portfolio helped reduce HbA1c*†1-7, hypoglycemic events*†8-9, work absenteeism*†10-11, and resource utilization*†10-14
among patients with type 1 and type 2 diabetes.

Get a one-page summary of our clinical evidence.

Stay up to date on the FreeStyle Libre portfolio.

Get in touch with our Medical Affairs team to learn more about the latest clinical evidence supporting the FreeStyle Libre portfolio.

Product images are for illustrative purposes only.

Medicare coverage is available for the FreeStyle Libre systems if their respective readers are used to review glucose data on some days every month. Medicare and other third party payor criteria apply.

Abbott provides this information as a courtesy; it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.

The FreeStyle Libre 2 system and FreeStyle Libre 3 system are indicated for patients ages 4 and older.

* Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore the study data is applicable to both products.

† Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore the study data is applicable to both products.

References: 1. Carlson AL, et al. BMJ Open Diabetes Res Care (2022): https://doi.org/10.1136/bmjdrc-2021-002590 2. Evans M, et al. Diabetes Ther (2022): https://doi.org/10.1007/s13300-022-01253-9 3. Wright, E. Diabetes Spectr (2021): https://doi.org/10.2337/ds20-0069 4. Kroger, J. Diabetes Ther (2020): https://doi.org/10.1007/s13300-019-00741-9 5. Tyndall, V. Diabetologia (2019): https://doi.org/10.1007/s00125-019-4894-1 6. Yaron, M. Diabetes Care (2019): https://doi.org/10.2337/dc18-0166 7. Campbell, F. Pediatr Diabetes (2018): https://doi.org/10.1111/pedi.12735 8. Haak, T. Diabetes Ther (2017): https://doi.org/10.1007/s13300-016-0223-6 9. Bolinder, J. The Lancet (2016): https://doi.org/10.1016/s0140-6736(16)31535-5 10. Fokkert, M. BMJ Open Diabetes Res Care (2019): https://doi.org/10.1136/bmjdrc-2019-000809 11. Charleer S, et al. Diabetes Care (2020): https://doi.org/10.2337/dc19-1610 12. Bergenstal, R. J Endocr Soc (2021): https://doi.org/10.1210/jendso/bvab013 13. Miller E, et al. AJMC (2021): https://doi.org/10.37765/ajmc.2021.88780 14. Deshmukh, H. Diabetes Care (2020): https://doi.org/10.2337/dc20-0738

ADC-76904 v1.0

Important Safety Information

FreeStyle Libre 14 day, FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.

The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.


No use of any Abbott trademark, trade name, or trade dress in this site may be made without prior written authorization of Abbott Laboratories, except to identify the product or services of the company.

This website and the information contained herein is intended for use by residents of the United States.

ADC-85718 v3.0